AbbVie to Host Second-Quarter 2025 Earnings Conference Call
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Morgan Stanley on Abbvie (ABBV) Buying Capstan: 'We view this acquisition as an incremental positive'
June 30, 2025 12:48 PM EDTMorgan Stanley analyst Terrance Flynn reiterated an Overweight rating and $250.00 price target on Abbvie (NYSE: ABBV).
The analyst comments "ABBV announced on 6/30 an agreement to acquire Capstan Therapeutics (private), a clinical-stage biotech focused on engineering cells in vivo (such as CAR-T) through RNA... More
